You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for LY 379268
LY 379268 is a highly selective group II mGlu receptor agonist (EC50 values are 2.69 and 4.48 nM for hmGlu2 and hmGlu3 respectively) that displays > 80-fold selectivity over group I and group III receptors. Provides protection against NMDA-mediated cell death in vitro and offers almost complete protection against CA1 hippocampal damage following global ischemia in gerbils. Orally and systemically active. LY379268 disodium salt also available.
Sold under license from Eli Lilly and Company
Technical Data for LY 379268
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for LY 379268
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for LY 379268
The following data is based on the product molecular weight 187.15. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.34 mL||26.72 mL||53.43 mL|
|5 mM||1.07 mL||5.34 mL||10.69 mL|
|10 mM||0.53 mL||2.67 mL||5.34 mL|
|50 mM||0.11 mL||0.53 mL||1.07 mL|
References for LY 379268
References are publications that support the biological activity of the product.
Bond et al (1999) LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal cerebral ischaemia. Neurosci.Lett. 273 191 PMID: 10515191
Bond et al (2000) Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanisms of action in vivo. J.Pharmacol.Exp.Ther. 294 800 PMID: 10945827
Collado et al (2002) (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 agonist with anxiolytic properties. J.Med.Chem. 45 3619 PMID: 12166935
If you know of a relevant reference for LY 379268, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LY 379268, LY 379268 supplier, selective, group, II, agonists, Group, Receptors, mGlu2, mGluR2, mGlu3, mGluR3, Glutamate, Metabotropic, LY379268, (Metabotropic), 2453, Tocris Bioscience
19 Citations for LY 379268
Citations are publications that use Tocris products. Selected citations for LY 379268 include:
Vinkers et al (2012) Lifelong CRF overproduction is associated with altered gene expression and sensitivity of discrete GABA(A) and mGlu receptor subtypes. Psychopharmacology (Berl) 219 897 PMID: 21833506
Hinzman et al (2012) Disruptions in the regulation of extracellular glutamate by neurons and glia in the rat striatum two days after diffuse brain injury. J Neurotrauma 29 1197 PMID: 22233432
Scholler (2017) Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation. Nat Commun 8 1967 PMID: 29213077
Chandrasekaran et al (2017) mGluR2/3 activation of the SIRT1 axis preserves mitochondrial function in diabetic neuropathy. Ann Clin Transl Neurol 4 844 PMID: 29296613
Moreno et al (2012) Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A-mGlu2) receptor heteromerization and its psychoactive behavioral function. Front Mol Neurosci 287 44301 PMID: 23129762
Sekizawa et al (2009) A novel postsynaptic group II metabotropic glutamate receptor role in modulating baroreceptor signal transmission. J Neurosci 29 11807 PMID: 19776267
Johnson (2017) Metabotropic glutamate receptor 2 inhibits thalamically-driven glutamate and DA release in the dorsal striatum. Neuropharmacology 117 114 PMID: 28159646
Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236
Moreno et al (2011) Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring. J Biol Chem 31 1863 PMID: 21289196
Erlandson et al (2015) The Functional Organization of Neocortical Networks Investigated in Slices with Local Field Recordings and Laser Scanning Photostimulation. Psychopharmacology (Berl) 10 e0132008 PMID: 26134668
Carbonaro et al (2015) The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. J Neurosci 232 275 PMID: 24985890
Durand et al (2011) Reduced cAMP, Akt activation and p65-c-Rel dimerization: mechanisms involved in the protective effects of mGluR3 agonists in cultured astrocytes. PLoS One 6 e22235 PMID: 21779400
Chen et al (2010) The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl) 209 343 PMID: 20217053
Garcia et al (2010) Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses DA depletion-induced dendritic spine loss. Cereb Cortex 20 2423 PMID: 20118184
Liberto et al (2011) mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum. Neuropharmacology 61 638 PMID: 21619889
Bellesi and Conti (2010) The mGluR2/3 agonist LY379268 blocks the effects of GLT-1 upregulation on prepulse inhibition of the startle reflex in adult rats. Neuropsychopharmacology 35 1253 PMID: 20072121
Kurita et al (2012) HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 15 1245 PMID: 22864611
Wang et al (2013) Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons. PLoS One 8 e61787 PMID: 23593498
Trepanier et al (2013) Group II metabotropic glutamate receptors modify N-MthD.-aspartate receptors via Src kinase. Sci Rep 3 926 PMID: 23378895
Do you know of a great paper that uses LY 379268 from Tocris? Please let us know.
Reviews for LY 379268
There are currently no reviews for this product. Be the first to review LY 379268 and earn rewards!
Have you used LY 379268?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.